

Table S1 Clinical Isolates Used in this Study

Serotype	Isolates tested (#)	Site of Isolation
3	3	Massachusetts, USA
4	3	Arizona, Israel
6A/C	7	Massachusetts, USA
6B	3	Massachusetts, USA
7F	1	Massachusetts, USA
9A	1	Massachusetts, USA
9V	1	Massachusetts, USA
10A	6	Massachusetts, USA
11A	10	Massachusetts, USA
14	3	Massachusetts, USA
15A	8	Massachusetts, USA
15B	6	Massachusetts, USA
15C	6	Massachusetts, USA
15F	1	Massachusetts, USA
16F	1	Massachusetts, USA
17F	1	Massachusetts, USA
18C	1	Massachusetts, USA
19A	13	Massachusetts, USA
19F	11	Massachusetts, USA
22F	8	Massachusetts, USA
23A	11	Massachusetts, USA
23B	5	Massachusetts, USA
23F	4	Massachusetts, USA
31	1	Massachusetts, USA
34	3	Massachusetts, USA
33F	3	Massachusetts, USA
35B	13	Massachusetts, USA
35F	4	Massachusetts, USA
38	2	Massachusetts, USA

Figure S1




Figure S1 Zeta potential of clinical isolates used in this study. Each dot represents one isolate and the corresponding serotype is shown on the horizontal axis. The mean value of isolates within same serotype was used in the study as a representative zeta potential for the serotype.

Figure S2




Figure S2 Correlation between number of high energy bonds required to generate one polysaccharide repeat unit and serotype-specific zeta potential. Energy/ repeat unit was obtained by analyzing known capsular polysaccharide structures and published in a previous study (Weinberger et al, PLoS Pathog 5(6): e1000476). Spearman's rank correlation coefficient (ρ) and the associated p value (p) are shown.